These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22110213)

  • 41. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
    Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
    Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
    Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
    Hirsh V; Major PP; Lipton A; Cook RJ; Langer CJ; Smith MR; Brown JE; Coleman RE
    J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Diagnostic value of bone metabolic markers ICTP and BAP in lung cancer patients with bone metastases].
    Xin Y; Han B; Lou J; Wu J; Niu Y
    Zhongguo Fei Ai Za Zhi; 2010 Oct; 13(10):947-53. PubMed ID: 20959067
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Comparative study of bone resorption markers for the diagnosis of bone metastasis in lung cancer].
    Nakamura H; Oishi S; Yagyu H; Morisako T; Kishi K; Tsuchida F; Adachi H; Sarashina G; Sudoh A; Hashimoto T; Matsuoka T
    Nihon Kokyuki Gakkai Zasshi; 2002 May; 40(5):355-9. PubMed ID: 12166253
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Urinary excretion of type I collagen cross-linked N-telopeptide and serum bone-specific alkaline phosphatase analysis to determine the correlation of age and back-pain related changes in elderly women.
    Kamimura M; Uchiyama S; Takahara K; Hashidate H; Kawaguchi A; Nakagawa H
    J Bone Miner Metab; 2005; 23(6):495-500. PubMed ID: 16261458
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer.
    Bayrak SB; Ceylan E; Serter M; Karadağ F; Demir E; Çildağ O
    Int J Clin Oncol; 2012 Apr; 17(2):112-8. PubMed ID: 21691728
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.
    Costa L; Demers LM; Gouveia-Oliveira A; Schaller J; Costa EB; de Moura MC; Lipton A
    J Clin Oncol; 2002 Feb; 20(3):850-6. PubMed ID: 11821470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data.
    Mountzios G; Ramfidis V; Terpos E; Syrigos KN
    Clin Lung Cancer; 2011 Nov; 12(6):341-9. PubMed ID: 21703936
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biochemical markers of bone turnover in patients with spinal metastases after resistance training under radiotherapy--a randomized trial.
    Rief H; Omlor G; Akbar M; Bruckner T; Rieken S; Förster R; Schlampp I; Welzel T; Bostel T; Roth HJ; Debus J
    BMC Cancer; 2016 Mar; 16():231. PubMed ID: 26983672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer.
    Horiguchi T; Tachikawa S; Kondo R; Hirose M; Teruya S; Ishibashi A; Banno K
    Jpn J Clin Oncol; 2000 Apr; 30(4):174-9. PubMed ID: 10830985
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discrimination of clinical stages in non-small cell lung cancer patients by serum HSP27 and HSP70: a multi-institutional case-control study.
    Zimmermann M; Nickl S; Lambers C; Hacker S; Mitterbauer A; Hoetzenecker K; Rozsas A; Ostoros G; Laszlo V; Hofbauer H; Renyi-Vamos F; Klepetko W; Dome B; Ankersmit HJ
    Clin Chim Acta; 2012 Jul; 413(13-14):1115-20. PubMed ID: 22465083
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer.
    Ulrich U; Rhiem K; Schmolling J; Flaskamp C; Paffenholz I; Sälzer H; Bauknecht T; Schlebusch H
    Arch Gynecol Obstet; 2001 Jan; 264(4):186-90. PubMed ID: 11205705
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A new approach for evaluating bone turnover in chronic kidney disease.
    Tolouian R; Hernandez GT; Chiang WY; Gupta A
    Eur J Intern Med; 2010 Jun; 21(3):230-2. PubMed ID: 20493428
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictive value of serum bone sialoprotein in patients with bone metastasis of non-small cell lung cancer.
    He JJ; Zhi K; Liu GF
    Onkologie; 2011; 34(11):584-8. PubMed ID: 22104154
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer.
    Huang J; Gu T; Ying J
    Int J Clin Oncol; 2017 Dec; 22(6):1015-1025. PubMed ID: 28677013
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Markers of bone turnover across a competitive season in female athletes: a preliminary investigation.
    Morgan A; Weiss Jarrett J
    J Sports Med Phys Fitness; 2011 Sep; 51(3):515-24. PubMed ID: 21904292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum cross-linked n-telopeptides of type 1 collagen (NTx) in patients with solid tumors.
    Jablonka F; Schindler F; Lajolo PP; Pinczowski H; Fonseca FL; Barbieri A; Massonetto LH; Katto FT; Del Giglio A
    Sao Paulo Med J; 2009 Jan; 127(1):19-22. PubMed ID: 19466290
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biochemical markers and skeletal metastases.
    Demers LM; Costa L; Lipton A
    Cancer; 2000 Jun; 88(12 Suppl):2919-26. PubMed ID: 10898335
    [TBL] [Abstract][Full Text] [Related]  

  • 60. N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.
    Ferreira AR; Alho I; Shan N; Matias M; Faria M; Casimiro S; Leitzel K; Ali S; Lipton A; Costa L
    Oncologist; 2016 Dec; 21(12):1418-1426. PubMed ID: 27534575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.